Myriad Genetics announces repurchase of $100 million shares

February 19, 2016

Two of these eight drugs managed to go over to the brain crossing the blood brain barrier that blocks most drugs from entering the brain. Scientists injected these two drugs twice daily into mice engineered to carry Parkinson??s-causing LRRK2 changes in their brain. After three weeks, they examined the mouse brains to see if nerve cells had died. One drug provided almost complete protection against nerve cell death, and another had about 80 percent fewer dead cells than in mock treated mice.

Ted Dawson, professor of neurology and physiology and scientific director of the Johns Hopkins Institute for Cell Engineering said, ???This data suggests that if you were to develop a safe drug, then you could potentially have a new treatment for Parkinson??s disease patients with LRRK2 mutations.??? ???One could envision generating compounds around that core structure to develop a relatively selective and potent inhibitor of LRRK2,??? Dawson said.

Dawson??s team was working in collaboration with researchers at Southern Methodist University to design more-specific inhibitors of LRRK2, and the group is aiming at licensing this technology. The drugs?? approval by the FDA for use in humans may still take years.

???We??re curing Parkinson??s disease in a mouse, and now we have to discover drugs that actually work in human neurons. Then we??ll hopefully be able to make the leap forward to get a treatment to work in humans,??? Dawson said.